The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved ...

Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian Therapeutic Goods Administration's approval of Kisunla, its novel Alzheimer ...

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's ...

The first ever drug treatment to target the underlying causes of Alzheimer’s disease has become the first alternative ...

Australia just approved the first new Alzheimer’s treatment in decades. But before patients get their hopes up, there’s a ...

A first-of-its-kind treatment to slow the symptoms of early Alzheimer's disease has been approved for use in Australia.The Therapeutic Goods Administration has registered pharmaceutical giant Eli ...

Health providers hope a new blood test for Alzheimer’s disease will lead to quicker and earlier diagnoses of the progressive ...